The immunizing agent requires only one application (Photo: KAMIL KRZACZYNSKI/AFP)
The expectation is that the arrival of vaccines from Jansen – who was scheduled for Tuesday but has been suspended – Further acceleration of the process of immunization of the Brazilian population, given its application in a single dose, is different from other vaccinations applied in the country. Vaccines from Pfizer / BioNTech and AstraZeneca / Oxford require two doses to complete the immunization course of the population.
last friday 11 Ceará Governor Camilo Santana (PT) announced Distributing 120,200 doses of Janssen’s vaccines, in partnership with US pharmaceutical company Johnson & Johnson, against Covid-19 to 184 municipalities in Ceará for application to the general population aged 30-44.
Vaccination against Covid-19 prevents illness when a person comes into contact with the virus, providing lasting immunity to individuals and reducing severe illness according to Janssen Brazil in response to PeopleStudies show that a vaccine exists 85% efficacy for severe cases and 100% protection against hospitalization and death from Covid-19, within 14 to 28 days after vaccination.
Tests have shown positive results regarding protection against the acute form of the disease in various regions, ages and multiple variants of the virus, including SARS-CoV-2 of the B.1.351 strain observed in South Africa.
Read more | Moterao is trying to register half a million people from Fortaleza without registering to get the vaccine
| Ciara has a new ordinance in effect: See what can and can’t be done from Monday
Another practical application of the vaccine is that it Cost-effective alternative to Pfizer vaccines, which requires special storage and freezing temperatures. Janssen’s studies indicate that the immunizing agent can be stored in refrigeratorsinstead of the freezer.
The company states that the vaccine can be stored for up to two years at a temperature -20°C, and up to three months at between 2°C and 8°C. This means that it can be distributed in line with the existing infrastructure for cold chain distribution and logistics for other medicines and vaccines.
studies
After the success of the ENSEMBLE 3 clinical trial, designed to evaluate the safety and efficacy of a candidate Janssen vaccine against Covid-19, the drug company was finally able to announce the efficacy and safety of its immunizing device.
The efficacy and safety data are based on 43,783 participants, including 468 cases with symptoms of Covid-19. Janssen’s filter against the disease was 85% effective in preventing the acute form of the disease in all studied regions (the United States, Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru) and South Africa).
Efficacy against the acute form of the disease increased over time with no cases reported in participants vaccinated after the 49th day. Also, according to the study, in addition to common side effects such as fever, serious adverse events were greater in participants who used the placebo than in those who used the candidate vaccine.
Janssen’s Covid-19 vaccine enhances Johnson & Johnson’s AdVac® vaccine platform, which has also been used to develop and manufacture Janssen’s newly approved Ebola vaccine and to develop a candidate vaccine for Zika, respiratory syncytial virus (RSV) and HIV.
AdVac® virus vector technology can induce robust and long-lasting immune, humoral and cellular responses, enabling the search for vaccines for diseases that are currently unavoidable or treatable.
“Wannabe internet buff. Future teen idol. Hardcore zombie guru. Gamer. Avid creator. Entrepreneur. Bacon ninja.”